Jeffrey S. Wefel, Renato Lenzi, Richard L. Theriault, Robert N. Davis and Christina A. Meyers The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma Cancer 100
Article first published online: 28 APR 2004 | DOI: 10.1002/cncr.20272
In a prospective, randomized, longitudinal trial, 61% of women with breast carcinoma exhibited a decline in cognitive function at the completion of a standard-dose regimen of adjuvant chemotherapy comprising 5-fluorouracil, doxorubicin, and cyclophosphamide. One year later, approximately 50% of the women who experienced cognitive declines demonstrated improved cognitive functioning, whereas the remaining 50% did not experience any change in cognitive functioning.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field